Strata Virtual Pitch Event: Startups shaping innovative treatments

Strata continues to host virtual pitch events to connect experienced global investors with the most disruptive startups across Europe. 

On 3rd June, 2026, we organized a pitch event comprising 17 investors from 7 countries, and four revolutionary startups, led by Tamas Szeker (Strata’s Innovation & Funding Growth Partner). We want to thank all of them for participating! You all provided really interesting insights about the innovative treatments field.

Pitching startups presented their solutions of personalised brain stimulation therapy, AI-Powered echocardiography automation, ​stem cell therapy for osteoarthritis and sleep disorder diagnostic platform.

Strata will organize new investor meetings during 2026 focused on other verticals, so we will promptly be informing our community.

Looking forward to seeing you all again!

Background information

20 startups have already presented at Strata’s pitching events in front of more than 130 investors. Strata pitch events attract European, US and Asian investors looking for the most scalable European startups in the deeptech, medtech and sustainability verticals, with a focus on impact investing. The format is dynamic, includes short pitches and an engaging experience for both startups and investors, which ignites follow-on conversations and investments.

Share this post

related post

Featured insights

Inside the ERMA Booster Call

The ERMA (European Raw Materials Alliance) Booster Call, managed by EIT Raw Materials, is a funding initiative for startups, scale-ups, SMEs, and large mining, processing,

Green Deal and Efficient Buildings
Featured insights

GREEN DEAL AND EFFICIENT BUILDINGS

The last call of the Horizon 2020 The European Commission has announced what will be the last and largest financing call of the Horizon 2020 framework

Featured insights

Should Universities become investors?

Some world leading Universities and R&D institutes have created their own investment vehicles. However, is this a feasible innovation instrument for research entities? Are the